دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?
R.Glynne-JonesM.Harrison
Epstein–Barr virus DNA detection by targeted sequencing in post-treatment plasma samples and prognosis of locally advanced nasopharyngeal cancer: implications for clinical research
P.Economopoulou1E.Lianidou2A.Psyrri1
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J.Pascual1G.Attard2F.-C.Bidard34G.Curigliano56L.De Mattos-Arruda78M.Diehn9A.Italiano101112J.Lindberg13J.D.Merker14C.Montagut15N.Normanno16K.Pantel17G.Pentheroudakis18S.Popat1920J.S.Reis-Filho21J.Tie2223J.Seoane2425N.Tarazona2627…N.C.Turner1920
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
K.Van Baelen12T.Geukens13M.Maetens1V.Tjan-Heijnen4C.J.Lord5S.Linn678F.-C.Bidard9F.Richard1W.W.Yang5R.E.Steele5S.J.Pettitt5C.Van Ongeval10M.De Schepper111E.Isnaldi1I.Nevelsteen12A.Smeets12K.Punie3L.Voorwerk1314…C.Desmedt1â€
Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial
P.Jimenez-Fonseca1R.Salazar2V.Valenti3P.Msaouel4A.Carmona-Bayonas5
Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasma
D.C.T.Chan123†W.K.J.Lam12345†E.P.Hui46B.B.Y.Ma46C.M.L.Chan123V.C.T.Lee123S.H.Cheng123W.Gai123P.Jiang1234K.C.W.Wong46F.Mo46B.Zee7A.D.King8Q.T.Le9A.T.C.Chan46K.C.A.Chan1234Y.M.D.Lo1234
Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials
D.Rischin12H.Mehanna3R.J.Young4M.Bressel25J.Dunn6J.Corry78P.Soni9T.Fulton-Lieuw3G.Iqbal6L.Kenny1011S.Porceddu1112C.Wratten13M.Robinson14B.J.Solomon124Trans-Tasman Radiation Oncology Group and the De-ESCALaTE HPV Trial Group
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
M.Marczyk12A.Mrukwa1C.Yau3D.Wolf34Y.-Y.Chen5R.Balassanian6R.Nanda7B.A.Parker8G.Krings3H.Sattar9J.C.Zeck10K.S.Albain11J.C.Boughey12M.C.Liu13A.D.Elias14A.S.Clark15S.J.Venters4S.Shad3…L.Pusztai2
Deciphering radiological stable disease to immune checkpoint inhibitors
J.Luo123‡S.Wu4‡H.Rizvi5Q.Zhang4J.V.Egger5J.C.Osorio1A.J.Schoenfeld16A.J.Plodkowski7M.S.Ginsberg7M.K.Callahan689C.Maher9A.N.Shoushtari69M.A.Postow69M.H.Voss610R.R.Kotecha610A.Gupta11R.Raja4M.G.Kris16M.D.Hellmann168â€
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Z.Bakouny1†C.Labaki1†S.Bhalla2†A.L.Schmidt1†J.A.Steinharter1J.Cocco2D.A.Tremblay2M.M.Awad1A.Kessler2R.I.Haddad1M.Evans3F.Busser1M.Wotman3C.R.Curran1B.S.Zimmerman2G.Bouchard1T.Jun2P.V.Nuzzo1…D.B.Doroshow2‡
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib
P.Tarantino1Q.Jin1E.A.Mittendorf2T.A.King2G.Curigliano3S.M.Tolaney1
First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report
F.L.Zhang1†S.S.Song2†J.Wang1P.Zhang1J.Li1
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression
C.Ngo12†T.Grinda3†A.Boilève23A.Levy24C.Le Pechoux4L.Haddag5A.Valent1T.Lazure6S.Briand7C.Honoré8M.Faron8O.Mir9R.Bahleda3B.Verret3A.Le Cesne3
Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference
M.Launay1J.Guitton2R.Balluet1A.Moreau3J.-M.Phelip4Y.Tholance3P.Gonzalo3
Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B.G.M.Hughes12E.Munoz-Couselo3L.Mortier4Å.Bratland5R.Gutzmer67O.Roshdy8R.González Mendoza9J.Schachter10A.Arance11F.Grange12N.Meyer13A.Joshi14S.Billan15P.Zhang16B.Gumuscu16R.F.Swaby16J.-J.Grob17
